Stiripentol (Diacomit) is an anticonvulsant drug that belongs to a different class of medicines called aromatic allylic alcohols. It is used to treat seizures in patients with Dravet syndrome.
Stiripentol Uses:
-
Dravet syndrome:
- Patients with Dravet syndrome, formerly known as severe myoclonic epilepsy in infancy, may receive clobazam and valproic acid as an adjunctive treatment for refractory generalised tonic-clonic seizures (Chiron 2000; Wirrell 2016).
Stiripentol (Diacomit) Dose in Adults
Note:
- Not appropriate for monotherapy.
- The dosage of concomitant clobazam and valproate may need adjustment.
- Systemic exposure is slightly higher with the suspension powder than that observed with capsules;
- patient monitoring is strictly recommended when changes between dosage forms are required (Canadian labeling).
Stiripentol (Diacomit) Dose in the treatment of Dravet syndrome as adjunctive therapy) :
- Oral: Usual: According to some experts, you should start with 10 to 15 mg/kg/day and work your way up to a goal dose of 50 mg/kg/day over the course of 2 to 4 weeks.
- Maximum dose: 3 g/day (manufacturer’s labeling).
- Given in two or three divided dosages each day, 50 mg/kg/day.
Stiripentol (Diacomit) Dose in Children
Note:
- FDA approved in combination with clobazam;
- international labeling (European Medicines Agency, Health Canada) suggested combination with clobazam and valproic acid.
- Other concomitant antiepileptic agents have been studied as well (eg, topiramate) and efficacy data are changing continuously; although, experts recommend avoiding sodium channel blockers (eg, carbamazepine) which may exacerbate seizures.
- The concomitant dosage of clobazam and/or valproate may need adjustment with initiation of stiripentol.
- Systemic exposure is slightly higher with the powder for suspension than that observed with capsules; patient monitoring is recommended when switching between dosage forms.
- Two strengths of powder packets are available (250 mg and 500 mg);
- may combine the two strengths to achieve the appropriate dosage; ensure appropriate product selection.
Stiripentol (Diacomit) Dose in the treatment of Dravet syndrome as adjunctive therapy:
-
Children and Adolescents: Limited data available in children <2 years of age:
- Oral: The maximum daily dose is 3,000 mg/day, which is given in two or three divided doses of 50 mg/kg/day.
- Some professionals advise starting with a lower dose of 10 to 15 mg/kg/day in divided doses and gradually increasing to the initial target dose of 50 mg/kg/day over the course of two to four weeks.
Pregnancy Risk Category: Not assigned
- Animal reproduction studies have shown that adverse events were reported. We have not found any information regarding the use of stiripentol in pregnancy.
- Stiripentol can be used with clobazam and valproic acids (off-label); see individual monographs to get more information.
- Monitoring of pregnancy and infant adverse reactions to stiripentol exposure is ongoing.
Use of stiripentol while breastfeeding
- It is unknown if stiripentol can be found in breast milk.
- Stiripentol can be used with clobazam and valproic acids (off-label); see individual monographs to get more information.
- According to the drug's manufacturer, the choice of whether to stop or continue breastfeeding during therapy must be made while taking into account both the advantages of the therapy for both the mother and the baby.
Stiripentol (Diacomit) Dose in Kidney Disease:
- The drug manufacturer's labeling does not include any dosage adjustments (has not yet been studied).
- Take care with mild impairment. Use caution.
- Patients with severe or moderate renal impairment should not use this product.
Stiripentol (Diacomit) Dose in Liver disease:
- The drug manufacturer's labeling does not contain any dosage adjustments (has not been tested).
- When mildly impaired, exercise caution; gradually increase the dose to control seizures and tolerability. The liver is the primary site of metabolism.
- This product should not be used by patients with severe or moderate hepatic impairment.
Note:
- Adverse reactions reported with combination (clobazam) therapy.
Common Side Effects of Stiripentol (Diacomit):
-
Central Nervous System:
- Drowsiness
- Agitation
- Ataxia
- Hypotonia
- Dysarthria
- Insomnia
-
Endocrine & Metabolic:
- Weight Loss
-
Gastrointestinal:
- Decreased Appetite
- Nausea
-
Hematologic & Oncologic:
- Decreased Platelet Count
- Neutropenia
-
Neuromuscular & Skeletal:
- Tremor
Less Common Side Effects of Stiripentol (Diacomit):
-
Central Nervous System:
- Aggressive Behavior
- Fatigue
-
Endocrine & Metabolic:
- Weight Gain
-
Gastrointestinal:
- Vomiting
- Sialorrhea
-
Respiratory:
- Bronchitis
- Nasopharyngitis
-
Miscellaneous:
- Fever
Contraindications to Stiripentol (Diacomit):
- Hypersensitivity to stiripentol and any other component of the formulation
Warnings and precautions
-
Weight loss/appetite
- Clinical trials have shown that weight loss and appetite reduction were observed in 46% of patients and 27% of those who had participated (mean age 9.2 years).
- Monitor the growth rate for pediatric patients.
- A 30% reduction in the dose of valproate may be helpful for weight loss and appetite control.
-
Blood dyscrasias
- In clinical trials, thrombocytopenia and neutropenia were observed. Monitor CBC during therapy.
-
Depression in the CNS:
- CNS depression can occur (eg, sleepiness, drowsiness), and may cause impairment of physical or mental abilities.
- Patients should be warned about driving or operating machinery that requires mental alertness.
- Consider adjusting the dosage of Clobazam or other antiseizure medications if you experience CNS depression while taking clobazam.
-
Suicidal thoughts:
- No matter the antiepileptic drug's intended use, a pooled analysis of these trials revealed an increase in suicidal thoughts and actions (incidence rate of 0.43% treated patients versus 0.24% placebo); this risk became apparent as early as one week after the drug was started and persisted for the majority of the trial's duration (most trials were less than 24 weeks).
- Watch out for any changes in behavior or thoughts that could indicate depression or suicidal thoughts. Notify your health care provider immediately if you notice these symptoms.
-
Hepatic impairment
- Patients with mild impairment should be cautious; the liver metabolism is the primary focus.
- Patients with severe or moderate hepatic impairment should not use this product.
-
Renal impairment
- Patients with mild impairment should be cautious; elimination of metabolites occurs primarily through the kidneys.
- Patients with severe or moderate renal impairment should not use this product.
Stiripentol: Drug Interaction
|
Abiraterone Acetate |
May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors). |
|
Agomelatine |
CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Agomelatine. |
|
Alizapride |
May enhance the CNS depressant effect of CNS Depressants. |
|
Bosentan |
May lower the serum level of CYP3A4 substrates (High risk with Inducers). |
|
Brexanolone |
Brexanolone's CNS depressing effects may be amplified by other CNS depressants. |
|
Brimonidine (Topical) |
CNS depressants may have an enhanced CNS depressant impact. |
|
Broccoli |
May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers). |
|
Bromopride |
May enhance the CNS depressant effect of CNS Depressants. |
|
Cannabidiol |
May enhance the CNS depressant effect of CNS Depressants. |
|
Cannabidiol |
CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Cannabidiol. |
|
Cannabis |
May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers). |
|
Cannabis |
May enhance the CNS depressant effect of CNS Depressants. |
|
Chlorphenesin Carbamate |
May enhance the adverse/toxic effect of CNS Depressants. |
|
CloBAZam |
Stiripentol serum concentration might rise. Stiripentol may raise the level of CloBAZam in the blood. |
|
Clofazimine |
May elevate CYP3A4 substrates' serum concentration (High risk with Inhibitors). |
|
CloZAPine |
The serum levels of CloZAPine may rise after using CYP1A2 Inhibitors (Moderate). |
|
CNS Depressants |
Other CNS depressants' harmful or toxic effects might be exacerbated. |
|
CYP1A2 Inducers (Moderate) |
May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers). |
|
CYP1A2 Inhibitors (Moderate) |
May decrease the metabolism of CYP1A2 Substrates (High risk with Inhibitors). |
|
CYP1A2 Substrates (High risk with Inhibitors) |
CYP1A2 Inhibitors (Moderate) may decrease the metabolism of CYP1A2 Substrates (High risk with Inhibitors). |
|
CYP2C19 Inducers (Moderate) |
May decrease the serum concentration of CYP2C19 Substrates (High risk with Inducers). |
|
CYP2C19 Inhibitors (Moderate) |
May decrease the metabolism of CYP2C19 Substrates (High risk with Inhibitors). |
|
CYP2C19 Substrates (High risk with Inhibitors) |
CYP2C19 Inhibitors (Moderate) may decrease the metabolism of CYP2C19 Substrates (High risk with Inhibitors). |
|
CYP3A4 Inducers (Moderate) |
May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). |
|
CYP3A4 Inhibitors (Moderate) |
May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors). |
|
Deferasirox |
May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). |
|
Deferasirox |
May elevate CYP1A2 substrates' serum concentration (High risk with Inhibitors). |
|
Dimethindene (Topical) |
CNS depressants may have an enhanced CNS depressant impact. |
|
Doxylamine |
CNS depressants may have an enhanced CNS depressant impact. Management: The producer of the pregnancy-safe drug Diclegis (doxylamine/pyridoxine) particularly advises against combining it with other CNS depressants. |
|
Dronabinol |
CNS depressants may have an enhanced CNS depressant impact. |
|
Esketamine |
CNS depressants may have an enhanced CNS depressant impact. |
|
Fosnetupitant |
May elevate CYP3A4 substrates' serum concentration (High risk with Inhibitors). |
|
HydrOXYzine |
May enhance the CNS depressant effect of CNS Depressants. |
|
Kava Kava |
May enhance the adverse/toxic effect of CNS Depressants. |
|
Lofexidine |
May enhance the CNS depressant effect of CNS Depressants. Management: Drugs listed as exceptions to this monograph are discussed in further detail in separate drug interaction monographs. |
|
Magnesium Sulfate |
May enhance the CNS depressant effect of CNS Depressants. |
|
MetyroSINE |
CNS Depressants may enhance the sedative effect of MetyroSINE. |
|
Mianserin |
May diminish the therapeutic effect of Anticonvulsants. |
|
Minocycline |
May enhance the CNS depressant effect of CNS Depressants. |
|
Nabilone |
May enhance the CNS depressant effect of CNS Depressants. |
|
Netupitant |
May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). |
|
Obeticholic Acid |
May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors). |
|
Orlistat |
May decrease the serum concentration of Anticonvulsants. |
|
Peginterferon Alfa-2b |
May elevate CYP1A2 substrates' serum concentration (High risk with Inhibitors). |
|
Piribedil |
Piribedil's CNS depressing effects may be enhanced by other CNS depressants. |
|
Pramipexole |
The sedative effects of pramipexole might be enhanced by CNS depressants. |
|
ROPINIRole |
The sedative effects of CNS depressants may increase those of ROPINIRole. |
|
Rotigotine |
Rotigotine's sedative effects may be boosted by CNS depressants. |
|
Rufinamide |
CNS depressants' harmful or toxic effects could be increased. Particularly, drowsiness and lightheadedness could be worsened. |
|
Sarilumab |
May lower the serum level of CYP3A4 substrates (High risk with Inducers). |
|
Selective Serotonin Reuptake Inhibitors |
Selective serotonin reuptake inhibitors may have a worsened or more hazardous effect when taken with CNS depressants. Particularly, there may be an increased risk of psychomotor impairment. |
|
Siltuximab |
May lower the serum level of CYP3A4 substrates (High risk with Inducers). |
|
Teriflunomide |
May lower the serum level of CYP1A2 substrates (High risk with Inducers). |
|
Tetrahydrocannabinol |
May enhance the CNS depressant effect of CNS Depressants. |
|
Tetrahydrocannabinol and Cannabidiol |
May enhance the CNS depressant effect of CNS Depressants. |
|
Tocilizumab |
May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). |
|
Trimeprazine |
May enhance the CNS depressant effect of CNS Depressants. |
|
Risk Factor D (Consider therapy modification) |
|
|
Blonanserin |
CNS Depressants may enhance the CNS depressant effect of Blonanserin. |
|
Buprenorphine |
|
|
Chlormethiazole |
May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used. |
|
Cilostazol |
CYP2C19 Inhibitors may increase the serum concentration of Cilostazol. Management: Consider reducing the cilostazol dose to 50 mg twice daily in patients who are also receiving inhibitors of CYP2C19. |
|
Citalopram |
CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Citalopram. Management: Limit citalopram dose to a maximum of 20 mg/day if used with a moderate CYP2C19 inhibitor. Patients using this combination should be monitored closely for evidence of citalopram toxicity (e.g., serotonin syndrome, QT prolongation, etc.). |
|
Clopidogrel |
CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Due to a risk for impaired clopidogrel effectiveness with such a combination, carefully consider the need for a moderate CYP2C19 inhibitor in patients receiving clopidogrel. Monitor patients closely for evidence of a diminished response to clopidogrel. |
|
CYP1A2 Inhibitors (Strong) |
May decrease the metabolism of CYP1A2 Substrates (High risk with Inhibitors). |
|
CYP2C19 Inducers (Strong) |
May increase the metabolism of CYP2C19 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling. |
|
CYP2C19 Inhibitors (Strong |
May decrease the metabolism of CYP2C19 Substrates (High risk with Inhibitors). |
|
CYP3A4 Inducers (Strong) |
May speed up CYP3A4 substrate metabolism (High risk with Inducers). Management: Take into account a substitute for one of the interfering medications. Certain contraindications may apply to some combinations. the relevant manufacturer's label. |
|
CYP3A4 Inhibitors (Strong) |
May slow down CYP3A4 substrate metabolism (High risk with Inhibitors). |
|
CYP3A4 Substrates (High risk with Inhibitors) |
Stiripentol may elevate CYP3A4 Substrates' serum levels (High risk with Inhibitors). Management: Due to the increased potential for side effects and toxicity, stiripentol should not be used with CYP3A4 substrates that are thought to have a narrow therapeutic index. Use of stiripentol with any CYP3A4 substrate necessitates closer observation. |
|
Dabrafenib |
May lower the serum level of CYP3A4 substrates (High risk with Inducers). Management: Where possible, look for substitutes for the CYP3A4 substrate. |
|
Dabrafenib |
May lower the serum level of CYP2C19 substrates (High risk with Inducers). Management: Where possible, look for substitutes for the CYP2C19 substrate. If concurrent therapy cannot be avoided, pay special attention to the substrate's clinical consequences (particularly therapeutic effects). |
|
Droperidol |
CNS depressants may have an enhanced CNS depressant impact. Consider lowering the dosage of droperidol or other CNS drugs (such as opioids or barbiturates) when they are used concurrently. In separate drug interaction monographs, exceptions to this monograph are covered in more detail. |
|
Enzalutamide |
May lower the serum level of CYP3A4 substrates (High risk with Inducers). Treatment: Enzalutamide should not be used concurrently with CYP3A4 substrates that have a limited therapeutic index. Enzalutamide use, like with the use of any other CYP3A4 substrate, should be done cautiously and under close observation. |
|
Enzalutamide |
May lower the serum level of CYP2C19 substrates (High risk with Inducers). For medications that CYP2C19 activates, active metabolite concentrations may decrease instead. Treatment: Enzalutamide should not be used concurrently with CYP2C19 substrates that have a limited therapeutic index. Enzalutamide use, like with the use of any other CYP2C19 substrate, should be done with caution and under close observation. |
|
Flunitrazepam |
Flunitrazepam's CNS depressing effects may be enhanced by other CNS depressants. |
|
HYDROcodone |
CNS Depressants may enhance the CNS depressant effect of HYDROcodone. Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. |
|
Lorlatinib |
May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Avoid concurrent use of lorlatinib with any CYP3A4 substrates for which a minimal decrease in serum concentrations of the CYP3A4 substrate could lead to therapeutic failure and serious clinical consequences. |
|
Mefloquine |
May reduce an anticonvulsant's therapeutic impact. Anticonvulsant serum concentrations may be reduced by mefloquine. Treatment: Mefloquine should not be used to prevent malaria in those who have a history of convulsions. With concurrent use, closely monitor anticonvulsant concentrations and therapeutic response. |
|
Methotrimeprazine |
CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants. Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established. |
|
MiFEPRIStone |
May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus. |
|
Mitotane |
May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane. |
|
Opioid Agonists |
CNS Depressants may enhance the CNS depressant effect of Opioid Agonists. Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. |
|
OxyCODONE |
CNS Depressants may enhance the CNS depressant effect of OxyCODONE. Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. |
|
Perampanel |
May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination. |
|
Pirfenidone |
CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Pirfenidone. Management: Use any such combination with caution and close monitoring for pirfenidone toxicity. Avoid the use of pirfenidone with moderate CYP1A2 inhibitors whenever CYP2C9, 2C19, 2C6, or 2E1 is also inhibited (either by the CYP1A2 inhibitor or by a third drug). |
|
Rasagiline |
Rasagiline's serum levels may rise in response to moderate CYP1A2 inhibitors. Treatment: Patients on mild CYP1A2 inhibitors should have their daily dose of rasagiline limited to 0.5 mg. |
|
Sodium Oxybate |
CNS depressants may have an enhanced CNS depressant impact. Management: Take into account substitutes for combined use. Reduce the doses of one or more medications when simultaneous use is necessary. It is not advised to use sodium oxybate with alcoholic beverages or hypnotic sedatives. |
|
St John's Wort |
May lower the serum level of CYP3A4 substrates (High risk with Inducers). Management: Take into account a substitute for one of the interfering medications. Certain contraindications may apply to some combinations. the relevant manufacturer's label. |
|
Suvorexant |
CNS Depressants may enhance the CNS depressant effect of Suvorexant. Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary. Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended. |
|
Tapentadol |
May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. |
|
TiZANidine |
TiZANidine's serum levels may rise in response to moderate CYP1A2 inhibitors. Treatment: Start adult dosages of tizanidine at 2 mg and increase by 2 to 4 mg increments, depending on the patient's response, if concurrent usage cannot be avoided. Watch out for tizanidine side effects, such as increased effects. |
|
Vemurafenib |
May elevate CYP1A2 substrates' serum concentration (High risk with Inhibitors). Management: If possible, look into alternatives to such combinations, especially if the CYP1A2 substrate has a relatively limited therapeutic index. Medicines marked as exclusions from this document are covered in separate monographs on drug interactions. |
|
Zolpidem |
The CNS depressing action of zolpidem may be enhanced by CNS depressants. Men with additional CNS depressants should lower their sublingual zolpidem dose to 1.75 mg under the Intermezzo brand. |
|
Risk Factor X (Avoid combination) |
|
|
Alcohol (Ethyl) |
Stiripentol may enhance the sedative effect of Alcohol (Ethyl). |
|
Alosetron |
Alosetron's serum levels may rise when taken with CYP1A2 Inhibitors (Moderate). |
|
Azelastine (Nasal) |
CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). |
|
Bromperidol |
May enhance the CNS depressant effect of CNS Depressants. |
|
Caffeine and Caffeine Containing Products |
Stiripentol may raise the levels of caffeine and products containing caffeine in the blood. |
|
CarBAMazepine |
Stiripentol may increase the serum concentration of CarBAMazepine. |
|
Conivaptan |
May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). |
|
Fusidic Acid (Systemic) |
May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). |
|
Idelalisib |
May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). |
|
Orphenadrine |
CNS Depressants may enhance the CNS depressant effect of Orphenadrine. |
|
Oxomemazine |
May enhance the CNS depressant effect of CNS Depressants. |
|
Paraldehyde |
CNS Depressants may enhance the CNS depressant effect of Paraldehyde. |
|
PHENobarbital |
May decrease the serum concentration of Stiripentol. |
|
Phenytoin |
Stiripentol may decrease the serum concentration of Phenytoin. |
|
Thalidomide |
CNS Depressants may enhance the CNS depressant effect of Thalidomide. |
|
Theophylline |
Stiripentol may increase the serum concentration of Theophylline. |
Monitoring parameters:
- CBC (prior to initiation and every 6 months or as clinically indicated thereafter);
- weight;
- growth rate in children.
How to administer Stiripentol (Diacomit)?
- Oral: Take 2 to 3 divided doses each day with a meal.
- Capsules have to be consumed whole together with a glass of water.
- Never open, chew, or crush capsules.
- Mix powder for suspension with one glass of water immediately.
- To ensure that there are no leftover medication, you can add a small amount (eg 25 mL) of water to the dosing cups.
Mechanism of action of Stiripentol (Diacomit):
- It is not known what mechanism causes anticonvulsant effects.
- GABAergic inhibitory neurotransmission may be enhanced by weak partial agonism, and/or positive allosteric stimulation of the gammaaminobutyric acids (GABA-A) receptors (Fisher 2009).
- It also inhibits multiple cytochrome P450 enzymes involved in the metabolism other anticonvulsants. Concurrent use could increase their systemic exposure or efficacy. Pharmacodynamics and Pharmacokinetics
Absorption:
- Well absorbed; high first-pass metabolism (Walker 1995).
- The maximum concentration achieved with suspension powder is slightly lower than the one reported with capsules (Diacomit prescribing info [Canada 2012]).
Protein binding:
- Plasma proteins 99%
Metabolism:
- Hepatic through demethylation, primarily via CYP1A2, 3A4, and glucuronidation. (Moreland 1986).
Bioavailability:
- 30% (Walker 1995)
Half-life elimination:
- Adults: 4.5 to 13 hours (dose-dependent)
Time to peak:
- Median: 2 to 3 hours
Excretion:
- Urine (73%, primarily metabolites); feces (18% as unchanged drug) (Moreland 1986)
International Brands of Stiripentol:
- Diacomit
Stiripentol Brand Names in Pakistan:
No Brands Available in Pakistan.
